A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2002
10/22/2002	US6469013 Therapeutic compounds
10/22/2002	US6469012 Pyrazolopyrimidinones for the treatment of impotence
10/22/2002	US6469006 Particularly for treating hiv infections
10/22/2002	US6468989 Gel compositions containing metronidazole
10/22/2002	US6468988 Composition that regulates and diminishes appetite and methods relating thereto
10/22/2002	US6468983 RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
10/22/2002	US6468980 Composition comprising cancer chemotherapeutic agent and potentiating agent selected from group consisting of vitamin c metabolites or ascorbic acid-derived furanones
10/22/2002	US6468974 Oligopeptides that provide desirable in vitro and in vivo growth hormone releasing activity and have at least one other desirable biological activity such as increased retention time
10/22/2002	US6468964 Administering to human or animal active agent capable of preventing or controlling acid and endotoxin accumulation in gastrointestinal tract, selected from antibiotics, enzymes, clays, probiotics, compounds which slow rate of passage
10/22/2002	US6468960 Therapeutic compositions and methods for enhancing angiogenesis
10/22/2002	US6468800 Systems and methods for rapidly identifying useful chemicals in liquid samples
10/22/2002	US6468756 Methods of identifying compounds that bind to SNORF25 receptors
10/22/2002	US6468737 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
10/22/2002	US6468540 Immunotherapeutic stress protein-peptide complexes against cancer
10/22/2002	US6468534 Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use
10/22/2002	US6468533 Polyclonal or monoclonal antibody that inhibits high mobility group 1 protein mediated activation of inflammatory cytokine cascade; sepsis
10/22/2002	US6468529 Fab fragment of a monoclonal antibody; binds to c-met receptor; cancer treatment
10/22/2002	US6468527 Biological bioadhesive composition and methods of preparation and use
10/22/2002	US6468504 Composition comprising methylphenidate and another drug
10/22/2002	US6468503 Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
10/22/2002	CA2406976A1 Active substance combination containing an opioid having a fentanyl-type structure and ketamine
10/20/2002	CA2382326A1 Therapeutic use of selective pde10 inhibitors
10/17/2002	WO2002082075A2 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
10/17/2002	WO2002082044A2 Method of imaging cell death in vivo
10/17/2002	WO2002081747A1 Method of examining steroid responsiveness
10/17/2002	WO2002081665A2 Implantation serine proteinases
10/17/2002	WO2002081649A2 ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
10/17/2002	WO2002081636A2 Protein modification and maintenance molecules
10/17/2002	WO2002081627A2 Methods of screening and using inhibitors of angiogenesis
10/17/2002	WO2002081494A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	WO2002081482A1 Compounds and methods for inhibiting mrp1
10/17/2002	WO2002081480A1 Compounds and pharmaceutical compositions for inhibiting mrp1
10/17/2002	WO2002081475A1 Jun kinase inhibitors
10/17/2002	WO2002081467A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
10/17/2002	WO2002081454A1 Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
10/17/2002	WO2002081415A2 Method for inhibiting metap2
10/17/2002	WO2002081005A2 Peritoneal dialysis fluid
10/17/2002	WO2002080985A1 Increasing retrievable fluid from a breast duct
10/17/2002	WO2002080981A2 Polynucleotide binding complexes comprising sterols and saponins
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080975A1 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
10/17/2002	WO2002080974A1 Novel medicinal use of cytokine production inhibitor
10/17/2002	WO2002080973A1 Composition for use in therapy of hard tissue of mammal and method of therapy thereof
10/17/2002	WO2002080971A1 Composition comprising an androgen receptor blocker and an insulin sensitizing agent and use thereof for treatment of polycystic ovary syndrome
10/17/2002	WO2002080969A1 Remedies for infant chronic arthritis-relating diseases
10/17/2002	WO2002080957A1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
10/17/2002	WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002	WO2002080940A2 Pharmacologically active strong acid solutions
10/17/2002	WO2002080937A1 Antineoplastic compositions comprising trk tyrosine kinase inhibitors and nucleotide analogs
10/17/2002	WO2002080936A1 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
10/17/2002	WO2002080935A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080912A1 Reconstitutable parenteral composition containing a cox-2 inhibitor
10/17/2002	WO2002080910A1 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
10/17/2002	WO2002080903A1 Functional role for cannabinoids in autonomic stability during sleep
10/17/2002	WO2002080900A1 Method for improving the well-being of poultry by in-ovo injection of carnitine
10/17/2002	WO2002080890A2 A jasmonate pharmaceutical composition for treatment of cancer
10/17/2002	WO2002080889A2 A combination dosage of a cyclooxygenase (cox) inhibitor, a vitamin d3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002080884A2 Powder inhaler formulations
10/17/2002	WO2002080859A2 Inhalation drug combinations
10/17/2002	WO2002080858A2 Use of kpv tripeptide for dermatological disorders
10/17/2002	WO2002080849A2 Chemotherapeutic induction of egr-1 promoter activity
10/17/2002	WO2002080676A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002	WO2002080663A1 Experimental animals for evaluation of therapeutic effects on corneal epithelial damages
10/17/2002	WO2002066468A3 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
10/17/2002	WO2002049626A3 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
10/17/2002	WO2002047493A3 Health promoting compositions
10/17/2002	WO2002044156A3 Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
10/17/2002	WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002	WO2002041894A3 Selective dopamine d4 receptor agonists for treating sexual dysfunction
10/17/2002	WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002	WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002	WO2002036733A9 Cd36 as a heat shock protein receptor and uses thereof
10/17/2002	WO2002036108A3 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases
10/17/2002	WO2002029061A3 G-protein coupled receptors
10/17/2002	WO2002019213A3 Method for treatment of migraine using pde5 inhibitors
10/17/2002	WO2002017891A3 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
10/17/2002	WO2002016417A3 Transgenic animal model for neurodegerative disease and uses thereof
10/17/2002	WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002	WO2002010192A9 Somatostatin analogues
10/17/2002	WO2001098354A3 Human receptors
10/17/2002	WO2001098344A3 Angiogenesis-modulating compositions and uses
10/17/2002	WO2001098323A3 G-protein coupled receptors
10/17/2002	WO2001096283A9 Hiv integrase inhibitors
10/17/2002	WO2001091778A3 Compositions for treating neck and shoulder discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins
10/17/2002	WO2001091736A3 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
10/17/2002	WO2001058241A9 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
10/17/2002	WO2001054723A9 Therapeutic method for reducing angiogenesis
10/17/2002	WO2001053330A9 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	US20020152485 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
10/17/2002	US20020152480 Alpha-synuclein super-mutants accelerate alpha-synuclein aggregation
10/17/2002	US20020151698 For diagnosis, prevention, and treatment of cancer, and neurological and immune disorders
10/17/2002	US20020151680 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
10/17/2002	US20020151598 Bronchodilating compositions and methods
10/17/2002	US20020151597 Formoterol, or a derivative; long term storage stability
10/17/2002	US20020151592 Long term administration of L-arginine, L-lysine or salts, and a polypeptide precursor which enhance the level of endogenous nitric oxide or intermediates in the NO induced relaxation pathway in the host
10/17/2002	US20020151591 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative useful in treatment of disorders associated with cognition impairment including, Alzheimer's, vascular dementia, Parkinson's disease etc
10/17/2002	US20020151589 Levodopa (l-dopa) ethyl ester, carbidopa or benserazide, a filler, a disintegrant, and a lubricant tablets used to treat Parkinson's disease

1 ... 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 ... 1151